There are plans for earlier diagnosis and faster treatment in England but experts worry about lack of staff.

"Dosing the first patient in our Phase 1/2 trial of NEO-811 in renal cell carcinoma marks a pivotal inflection point for Neomorph, representing the first clinical evaluation of an asset from our ...

Neomorph begins human testing of a molecular glue therapy that selectively removes cancer-driving proteins, targeting clear cell renal cell carcinoma.

In a groundbreaking development for cancer treatment, Neomorph, a local biotech firm, has begun clinical trials for its innovative molecular glue, NEO-811. This nove ...

Investing.com -- Evogene Ltd. (NASDAQ:EVGN) stock surged 12.5% Wednesday following the announcement of an exclusive worldwide ...

Blood and saliva tests to detect cancer before symptoms begin ‘could be part of NHS screening within a decade’ - The ...

The government will also scale up robotic-assisted procedures and offer more patients genomic testing to allow for more ...

This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it’s putting that claim to the test. After attracting global attention from ...

In this phase 2a study, researchers aimed to determine whether donor fecal microbiota transplantation improved survival in mRCC patients receiving immunotherapy.

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative ...

Biomica, a subsidiary of Evogene, and Lishan Biotech have agreed to a worldwide, exclusive licensing deal for a microbiome-based therapeutic.

Early detection cancer tests ‘could be part of NHS screening within a decade’ - The Government has set out how it intends to transform cancer detection and treatment in a new 10-year plan.